# MBX Biosciences, Inc. Common Stock (MBX)

> MBX Biosciences, Inc. Common Stock (MBX) trades at $55.94 (+2.62%) as of 7:30:02 PM EST on Nov 13, 2026, +10.31% over the past month. Market cap is $2.71B, with 7.9 days to cover in short interest.

Canonical: https://massive.com/quote/mbx
Data as of: 2026-11-14T00:30:02.312Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$55.94** +1.43 (+2.62%)
As of 7:30:02 PM EST on Nov 13, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How MBX Biosciences, Inc. Common Stock (MBX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +2.62% |
| 1W | +8.94% |
| 1M | +10.31% |
| YTD | +77.36% |
| 1Y | +125.66% |
| 52-wk range | $23.07 – $72.64 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for MBX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $52.94 – $57.11 |
| Open | $54.49 |
| Prev close | $54.51 |
| Volume | 855.45K |
| Market cap | $2.71B |
| Shares out | 48.16M |

## Insider trading

[MBX Biosciences, Inc. Common Stock (MBX) insider trading](https://massive.com/quote/mbx/insider-trading.md): open-market Form 4 buys and sells by MBX Biosciences, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events MBX Biosciences, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · Investor presentation
  “On November 9, 2026, the Company updated its corporate presentation. The corporate presentation is available in the "Investors" section of the Company's website at www.mbxbio.com and is furnished as Exhibit 99.2 to this Current Report on Form 8-K.”
- Oct 22, 2026 · Equity compensation grant
  “In connection with his appointment as a non-employee director, Mr. Radovich will receive compensation, including an initial award of a non-qualified stock option to purchase 18,200 shares of the Company's common stock, to be granted on the appointment date of October 20, 2026.”
- Aug 6, 2026 · Investor presentation
  “On August 6, 2026, the Company updated its corporate presentation. The corporate presentation is available in the "Investors" section of the Company's website at www.mbxbio.com and is furnished as Exhibit 99.2 to this Current Report on Form 8-K.”
- Jul 13, 2026 · Equity compensation grant
  “In addition, Mr. Hoerter will be granted equity awards on August 3, 2026. The equity awards will consist of (i) nonqualified stock options to purchase 331,000 shares of the Company's Common Stock, and (ii) a restricted stock unit award covering 71,000 shares of the Company's Common Stock under the 2024 Plan.”
- Jun 12, 2026 · Investor presentation
  “On June 12, 2026 at 8:00 a.m. E.T., the Company will host a conference call and webcast to discuss the one-year data from the Phase 2 Avail™ and open-label extension clinical trials. A copy of the presentation from the event will be available in the 'Investors' section of the Company's website at www.mbxbio.com and is furnished as Exhibit 99.2.”

## MBX short interest

How heavily MBX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.9 |
| Short interest | 4.29M |
| Avg volume | 542.47K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## MBX news

The latest news and headlines about MBX Biosciences, Inc. Common Stock (MBX).

- [MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism](https://www.globenewswire.com/news-release/2026/06/12/3310975/0/en/MBX-Biosciences-Announces-One-Year-Data-Demonstrating-Sustained-Benefit-of-Once-Weekly-Canvuparatide-as-a-Potential-PTH-Replacement-Therapy-in-Chronic-Hypoparathyroidism.html) · GlobeNewswire Inc. · Jun 12, 2026 · positive sentiment
- [AstraZeneca's Rare Disease Drug Shows Reduced Dependence On Calcium Supplements](https://www.benzinga.com/news/health-care/26/05/52488380/astrazenecas-rare-disease-drug-shows-reduced-dependence-on-calcium-supplements?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · May 12, 2026 · positive sentiment
- [MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing](https://www.globenewswire.com/news-release/2026/05/11/3291731/0/en/MBX-Biosciences-Provides-Obesity-Portfolio-Update-Including-Initial-Phase-1-Data-for-MBX-4291-Supporting-Potential-for-Once-Monthly-Dosing.html) · GlobeNewswire Inc. · May 11, 2026 · positive sentiment
- [MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://www.globenewswire.com/news-release/2026/04/03/3267994/0/en/MBX-Biosciences-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html) · GlobeNewswire Inc. · Apr 3, 2026 · positive sentiment
- [This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones](https://www.fool.com/coverage/filings/2025/12/03/this-biotech-fund-just-dumped-usd14-8-million-in-mbx-biosciences-right-before-key-2026-milestones/?source=iedfolrf0000001) · The Motley Fool · Dec 3, 2025 · neutral sentiment

## About MBX Biosciences, Inc. Common Stock

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 63 |
| Listed | Sep 13, 2024 |

[Company website](https://www.mbxbio.com)

## FAQ

### What is the MBX Biosciences, Inc. Common Stock (MBX) stock price today?

MBX Biosciences, Inc. Common Stock (MBX) is trading at $55.94 (+2.62% on the day) as of 7:30:02 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is MBX Biosciences, Inc. Common Stock?

MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders.

### What is the short interest in MBX?

As of Oct 30, 2026, MBX has 4.29M shares short and 7.9 days to cover.

### What exchange is MBX listed on?

MBX Biosciences, Inc. Common Stock (MBX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time MBX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=MBX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [MBX Biosciences, Inc. Common Stock (MBX) insider trading](https://massive.com/quote/mbx/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms